GlassScriptPhysician profile
Irma E Rasmussen
NPI 1144287236
$2,975.75
in general payments reported to CMS, 2019-2025
28 companies · $912 in 2025
The $912 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.01 · 2020: $21.55 · 2021: $168 · 2022: $472 · 2023: $559 · 2024: $750 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $575.84 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $557.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $539.29 | 2019-2025 | |
| Lilly USA, LLC | $203.34 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.50 | 2021-2025 | Jardiance |
| Shield Therapeutics INC | $102.89 | 2023-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $91.36 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $83.69 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $80.37 | 2021-2023 | Xarelto |
| Glaxosmithkline, LLC. | $70.50 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $69.19 | 2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $65.92 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Amgen INC. | $61.99 | 2023-2025 | Repatha, Repatha, Otezla |
| Sumitomo Pharma America, INC. | $46.00 | 2025 | Gemtesa |
| Verona Pharma, INC. | $29.81 | 2025 | Ohtuvayre |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Access Pro Medical, LLC | $29.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.58 | 2023 | Eliquis |
| Gilead Sciences, INC. | $23.81 | 2021 | |
| Medtronic, INC. | $22.51 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.49 | 2019 | |
| Seqirus USA INC | $20.00 | 2022 | |
| Mylan Specialty L.P. | $17.30 | 2022 | |
| Merck Sharp & Dohme LLC | $16.37 | 2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Biohaven Pharmaceutical Holding Company LTD. | $15.57 | 2022 | |
| Lucid Diagnostics INC. | $13.69 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.66 | 2025 | Zoryve |
| Vbi Vaccine (Delaware) INC. | $12.98 | 2022 | |
| Dynavax Technologies Corporation | $6.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irma Rasmussen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.